Antibody Information
General Information of This Antibody
| Antibody ID | ANTI0GWVCW |
|||||
|---|---|---|---|---|---|---|
| Antibody Name | hCTM01 |
|||||
| Antigen Name | Muc1 |
Antigen Info | ||||
| Click to Show/Hide the Sequence Information of This Antibody | ||||||
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
CMB-401 [Phase 2 (discontinued)]
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Objective Response Rate (ORR) |
0%
|
|||
| Patients Enrolled |
Platinum-sensitive EOC (recurrence >6 months after completion of an initial platinumcontaining chemotherapy regimen).
|
||||
| Administration Dosage |
Initial infusion of 35 mg/m2 of hCTM01 (anti-PEM antibody not conjugated to calicheamicin) over a period of 15 min, followed 45 min later (60 min from the start of the initial infusion) by an infusion of 16 mg/m2 of CMB-401 over an additional 60 min, up to 7 cycles, with 4 weeks between cycles.
|
||||
| Experiment 2 Reporting the Activity Date of This ADC | [2] | ||||
| Patients Enrolled |
EOC refractory to or unsuitable for platinum/standard therapy; with a WHO performance status of 0-2; life expectancy of more than three months and fulfilling other standard eligibility criteria.
|
||||
| Administration Dosage |
Up to four cycles of a dual infusion of 35.00 mg/m2 hCTMO1 'predose' followed by doses of CMB-401 which were increased for each cohort, CMB-401 dosing commenced at 2 mg/m2 and progressed via seven cohorts to 16.00 mg/m2.
|
||||
References